New hope for hepatitis b patients with normal ALT: TMF drug trial underway
NCT ID NCT05797714
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called Tenofovir Amibufenamide (TMF) in 200 adults with chronic hepatitis B who have normal liver enzyme levels (ALT). The goal is to see if TMF can lower the virus to undetectable levels and possibly clear the hepatitis B surface antigen. Participants are randomly assigned to receive TMF or no treatment, and results are measured after 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tenofovir Amibufenamide (TMF)
What this could lead to
If successful, this could offer a treatment option for hepatitis B patients with normal liver enzymes, potentially suppressing the virus and even clearing the surface antigen.
What could go wrong
This is an early-stage trial with no phase designation and only 200 participants. The drug may not work better than no treatment, and long-term safety is not yet established.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing You'An Hospital, Capital Medical University
Beijing, China
-
Fuyang Second People's Hospital
Fuyang, China
-
Jiangsu Province Hospital
Nanjin, China
-
LiShui People's Hospital of Zhejiang Province
Lishui, China
-
People's Hospital of Dongyang City
Dongyang, China
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai, China
-
Shanghai East Hospital
Shanghai, China
-
The Fifth People's Hospital of Suzhou
Suzhou, China
-
The Fifth People's Hospital of Wuxi
Wuxi, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, China
-
The First People's Hospital of Xiaoshan District, Hangzhou, Zhejiang Province
Hangzhou, China
-
The Second Xiangya Hospital, Central South University
Changsha, Hunan, China